Trial intelligence / Profile preview

ABT-494 vs methotrexate in methotrexate-naive moderate-to-severe rheumatoid arthritis

CTR20170490Phase 3Completed

Sponsor
AbbVie Inc.
Start
Jun 2017
Modality
Small Molecules
Countries
1
01

Overview

A Phase 3 trial of upadacitinib in rheumatoid arthritis (RA), sponsored by AbbVie Inc.. Started Jun 2017; status: completed.

02

Drugs

upadacitinib
03

Conditions

rheumatoid arthritis (RA)

Beyond the preview

Go deeper on CTR20170490.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on CTR20170490.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call